LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Home・Lista de Ações・BioNTech SE ADR

BioNTech SE ADR

Fechado

SetorSaúde

92.77 0.5

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

91.14

Máximo

93.03

Indicadores-chave
By Trading Economics
Rendimento	-717M -416M
Vendas	-1B 183M
EPS	-1.821
Margem de lucro	-227.462
Funcionários	6,772
EBITDA	253M 464M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+51.41% upside

Dividendos
By Dow Jones
Próximos Ganhos	4 de ago. de 2025

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-1.8B 23B
Abertura anterior	92.27
Fecho anterior	92.77

Sentimento de Notícias

By Acuity

58%

42%

150 / 382 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

92.4 / 103.5 Suporte e Resistência

BioNTech SE ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de fev. de 2025, 18:52 UTC

Grandes Movimentos do Mercado

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

15 de nov. de 2024, 10:28 UTC

Grandes Movimentos do Mercado

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

5 de mai. de 2025, 15:13 UTC

Conversa de Mercado

Ganhos

Narrower Guidelines for Covid-19 Booster Wouldn't Limit BioNTech's Customer Base Much -- Market Talk

15 de nov. de 2024, 11:14 UTC

Conversa de Mercado

U.S. Vaccine Stocks Fall After Trump Picks Vaccine Skeptic RFK Jr as Health Department Head-- Market Talk

15 de nov. de 2024, 10:34 UTC

Conversa de Mercado

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

5 de ago. de 2024, 10:02 UTC

Ganhos

BioNTech Sees 2024 R&D Expenses EUR2.4B-EUR2.6B >BNTX

5 de ago. de 2024, 10:01 UTC

Ganhos

BioNTech Backs 2024 View of Rev EUR2.5B-EUR3.1B >BNTX

5 de ago. de 2024, 10:01 UTC

Ganhos

BioNTech: Invested EUR525.6M, or About 90% of 2Q R&D Spend, in Non-Covid-19 Related Activities >BNTX

5 de ago. de 2024, 10:00 UTC

Ganhos

BioNTech 2Q-End Cash, Equivalents, Security Investments EUR18.5 Billion >BNTX

5 de ago. de 2024, 09:59 UTC

Ganhos

BioNTech 2Q Loss EUR807.8M >BNTX

5 de ago. de 2024, 09:59 UTC

Ganhos

BioNTech 2Q Loss/Shr EUR3.36 >BNTX

5 de ago. de 2024, 09:59 UTC

Ganhos

BioNTech 2Q Rev EUR128.7M >BNTX

Comparação entre Pares

Variação de preço

BioNTech SE ADR Previsão

Preço-alvo

By TipRanks

51.41% parte superior

Previsão para 12 meses

Média 139.81 USD 51.41%

Máximo 171 USD

Mínimo 110 USD

Com base em 18 analistas de Wall Street que oferecem metas de preço de 12 meses para BioNTech SE ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

18 ratings

Comprar

Manter

Vender

Com base em 18 analistas que deram avaliações de ações para BioNTech SE ADR - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

92.4 / 103.5Suporte e Resistência

Recent bearish events outweigh bullish events.

Sentimento

By Acuity

150 / 382 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac